Current Report Filing (8-k)
June 27 2019 - 07:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 26, 2019
Verrica Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-38529
|
|
46-3137900
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
10 North High Street, Suite 200
West Chester, PA
|
|
19380
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (484)
453-3300
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
|
|
|
|
|
Title of each class
|
|
Trading
symbol
|
|
Name of each exchange
on which registered
|
Common Stock
|
|
VRCA
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 7.01
|
Regulation FD Disclosure
|
On June 26, 2019, Verrica Pharmaceuticals Inc. (the Company) issued a press release reporting positive topline results from the Phase 2
clinical study of
VP-102
in patients with common warts, as well as information regarding a conference call to discuss these results and other clinical updates. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form
8-K.
A copy of the presentation that will accompany the conference call is furnished herewith as Exhibit 99.2 to this Current Report on Form
8-K.
The information included in this Item 7.01 of this Current Report on Form
8-K,
including the attached Exhibit 99.1 and Exhibit 99.2, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Verrica Pharmaceuticals Inc.
|
|
|
|
|
Date: June 27, 2019
|
|
|
|
|
|
/s/ Chris Degnan
|
|
|
|
|
|
|
Chris Degnan
|
|
|
|
|
|
|
Chief Financial Officer
|
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Mar 2023 to Mar 2024